Hypertrophy of the ligament flavum in degenerative lumbar stenosis associated with the increased expression of fractalkine (CX3CL1)/CX3CR1 chemokine

References

• Mazanec DJ. Back pain: medical evaluation and therapy. Cleve Clin J Med 1995;162:163–8
   Google Scholar
• Szpalski M, Gunzburg R. The role of surgery in the management of low back pain. Baillieres Clin Rheumatol 1998;12:141–59
   PubMedGoogle Scholar
• Kosaka H, Sairyo K, Biyani A, Leaman D, Yeasting R, Higashino K, Sakai T, Katoh S, Sano T, Goel VK, Yasui N. Pathomechanism of loss of elasticity and hypertrophy of lumbar ligamentum flavum in elderly patients with lumbar spinal canal stenosis. Spine 2007;32:2805–11
   PubMed Web of Science ®Google Scholar
• Sairyo K, Biyani A, Goel VK, Leaman DW, Booth R Jr, Thomas J, Ebraheim NA, Cowgill IA, Mohan SE. Lumbar ligamentum flavum hypertrophy is due to accumulation of inflammation-related scar tissue. Spine 2007;32:E340–7
   PubMed Web of Science ®Google Scholar
• Oh IS, Ha KY. Matrix metalloproteinase-3 on ligamentum flavum in degenerative lumbar spondylolisthesis. Spine 2009;34:E552–7
   Google Scholar
• Park JB, Lee JK, Park SJ, Riew KD. Hypertrophy of ligamentum flavum in lumbar spinal stenosis associated with increased proteinase inhibitor concentration. J Bone Joint Surg Am 2005;87:2750–7
   PubMedGoogle Scholar
• Sairyo K, Biyani A, Goel V, Leaman D, Booth R Jr, Thomas J, Gehling D, Vishnubhotla L, Long R, Ebraheim N. Pathomechanism of ligamentum flavum hypertrophy: a multidisciplinary investigation based on clinical, biomechanical, histologic, and biologic assessments. Spine 2005;30:2649–56
   PubMed Web of Science ®Google Scholar
• Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997;385:640–4
   PubMed Web of Science ®Google Scholar
• Fraticelli P, Sironi M, Bianchi G, D’Ambrosio D, Albanesi C, Stoppacciaro A, Chieppa M, Allavena P, Ruco L, Girolomoni G, Sinigaglia F, Vecchi A, Mantovani A. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 2001;107:1173–81
   PubMed Web of Science ®Google Scholar
• Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, Nomiyama H, Schall TJ, Yoshie O. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997;91:521–30
   PubMed Web of Science ®Google Scholar
• Fong AM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T, Patel DD. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 1998;188:1413–19
   PubMed Web of Science ®Google Scholar
• Haskell CA, Cleary MD, Charo IF. Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction: rapid flow arrest of CX3CR1-expressing cells is independent of G-protein activation. J Biol Chem 1999;274:10053–8
   PubMed Web of Science ®Google Scholar
• Nishimura M, Umehara H, Nakayama T, Yoneda O, Hieshima K, Kakizaki M, Dohmae N, Yoshie O, Imai T. Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J Immunol 2002;168:6173–80
   PubMed Web of Science ®Google Scholar
• Braunersreuther V, Mach F, Steffens S. The specific role of chemokines in atherosclerosis. Thromb Haemost 2007;97:714–21
   PubMed Web of Science ®Google Scholar
• Shimoda S, Harada K, Niiro H, Taketomi A, Maehara Y, Tsuneyama K, Kikuchi K, Nakanuma Y, Mackay IR, Gershwin ME, Akashi K. CX3CL1 (fractalkine): a signpost for biliary inflammation in primary biliary cirrhosis. Hepatology 2010;51:567–75
   PubMed Web of Science ®Google Scholar
• Suzuki F, Kubota T, Miyazaki Y, Ishikawa K, Ebisawa M, Hirohata S, Ogura T, Mizusawa H, Imai T, Miyasaka N, Nanki T. Serum level of soluble CX3CL1/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activity. Arthritis Res Ther 2012;14:R48
   PubMed Web of Science ®Google Scholar
• Xuan W, Liao Y, Chen B, Huang Q, Xu D, Liu Y, Bin J, Kitakaze M. Detrimental effect of fractalkine on myocardial ischaemia and heart failure. Cardiovasc Res 2011;92:385–93
   PubMed Web of Science ®Google Scholar
• Fukuyama S, Nakamura T, Ikeda T, Takagi K. The effect of mechanical stress on hypertrophy of the lumbar ligamentum flavum. J Spinal Disord 1995;8:126–30
   PubMedGoogle Scholar
• Zhong ZM, Zha DS, Xiao WD, Wu SH, Wu Q, Zhang Y, Liu FQ, Chen JT. Hypertrophy of Ligamentum Flavum in lumbar spine stenosis associated with the increased expression of connective tissue growth factor. J Orthop Res 2011;29:1592–7
   PubMed Web of Science ®Google Scholar
• Cockwell P, Chakravorty SJ, Girdlestone J, Chakravorty SJ, Savage CO. Fractalkine expression in human renal inflammation. J Pathol 2002;196:85–90
   PubMed Web of Science ®Google Scholar
• Sawai H, Park YW, He X, Goronzy JJ, Weyand CM. Fractalkine mediates T cell-dependent proliferation of synovial fibroblasts in rheumatoid arthritis. Arthritis Rheum 2007;56:3215–25
   PubMed Web of Science ®Google Scholar
• Shimizu K, Furuichi K, Sakai N, Kitagawa K, Matsushima K, Mukaida N, Kaneko S, Wada T. Fractalkine and its receptor, CX3CR1, promote hypertensive interstitial fibrosis in the kidney. Hypertens Res 2011;34:747–52
   PubMed Web of Science ®Google Scholar
• Volin MV, Woods JM, Amin MA, Connors MA, Harlow LA, Koch AE. Fractalkine: a novel angiogenic chemokine in rheumatoid arthritis. Am J Pathol 2001;159:1521–30
   PubMed Web of Science ®Google Scholar
• Chen YM, Lin SL, Chen CW, Chiang WC, Tsai TJ, Hsieh BS. Tumor necrosis factor-alpha stimulates fractalkine production by mesangial cells and regulates monocyte transmigration: down-regulation by cAMP. Kidney Int 2003;63:474–86
   PubMed Web of Science ®Google Scholar
• Matsumiya T, Ota K, Imaizumi T, Yoshida H, Kimura H, Satoh K. Characterization of synergistic induction of CX3CL1/fractalkine by TNF-alpha and IFN-gamma in vascular endothelial cells: an essential role for TNF-alpha in post-transcriptional regulation of CX3CL1. J Immunol 2010;184:4205–14
   PubMed Web of Science ®Google Scholar
• Ramsey RH. The anatomy of the ligamenta flavum. Clin Orthop 1966;44:129–40
   PubMedGoogle Scholar
• Yahia LH, Garzon S, Strykowski H, Rivard CH. Ultrastructure of the human interspinous ligament and ligamentum flaveum: a preliminary study. Spine 1990;15:262–8
   PubMed Web of Science ®Google Scholar
• Yoshida M, Shima K, Taniguchi Y, Tamaki T, Tanaka T. Hypertrophied ligament flavum in lumbar spinal canal stenosis. Pathogenesis and morphologic and immunohistochemical observation. Spine 1992;17:1353–60
   PubMed Web of Science ®Google Scholar
• Kosaka H, Sairyo K, Biyani A, Leaman D, Yeasting R, Higashino K, Sakai T, Katoh S, Sano T, Goel VK, Yasui N. Pathomechanism of loss of elasticity and hypertrophy of lumbar ligamentum flavum in elderly patients with lumbar spinal canal stenosis. Spine 2007;32:2805–11
   PubMed Web of Science ®Google Scholar
• Bachstetter AD, Morganti JM, Jernberg J, Schlunk A, Mitchell SH, Brewster KW, Hudson CE, Cole MJ, Harrison JK, Bickford PC, Gemma C. Fractalkine and CX 3 CR1 regulate hippocampal neurogenesis in adult and aged rats. Neurobiol Aging 2011;32:2030–44
   PubMed Web of Science ®Google Scholar
• Raoul W, Auvynet C, Camelo S, Guillonneau X, Feumi C, Combadière C, Sennlaubs F. CCL2/CCR2 and CX3CL1/CX3CR1 chemokine axes and their possible involvement in age-related macular degeneration. J Neuroinflammation 2010;7:87 doi: 10.1186/1742-2094-7-87
   PubMed Web of Science ®Google Scholar